Generics are grabbing an increasing market share, but overall spending is actually falling. (Photo: Getty)
Generic drugs, with their lower prices, are definitely being used more. That's the good news.
But the bad news is that the cost of brand-name drugs with high price tags is accounting for a huge proportion of drug spending. That's according to Modern Healthcare, which reports that overall drug spending only rose by 2 percent from 2016 to 2017—less than in earlier years.
But that increase “was largely due to branded-drug price hikes, according to an update of the Blue Cross and Blue Shield Association's study of medical claims of more than 40 million members.” In fact, says the report, during that period of time, spending on both branded patent-protected drugs and branded specialty drugs increased 5 percent and 10 percent, respectively.
In addition, brand-name prescription drugs only accounted for 17 percent of total prescriptions filled in 2017, but their costs took up some 79 percent of total pharmaceutical spending. Branded patent-protected prescription drugs made up 52 percent of branded prescription drugs filled, but accounted for 66 percent of total branded-drug spending.
And brand-name specialty drugs only made up 3 percent of branded-drug prescriptions filled, but ate up 34 percent of total branded-drug spending, at $27 billion.
Generics, meanwhile, are grabbing an increasing market share, climbing to 83 percent of prescriptions filled. Their share of total prescriptions filled was 66 percent in 2010, but branded pharmaceuticals' price hikes are overwhelming greater usage of lower-cost alternatives. Total spending on generic drugs has actually fallen 3 percent since 2016, while branded prescription drug spending is up 4 percent.
“Given the increase in generics, we should be in a fairly strong negative downturn in overall spending. But we're not,” Brian Harvey, executive director of the Blues' Health of America research initiative, which came out with the study, said in a statement.
Harvey added, “It's not negative because of the upward trend in the branded patent-protected space, particularly in the specialty space.”
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
Marlene Satter
Marlene Y. Satter has worked in and written about the financial industry for decades.
